The Pine Tree, News for Calaveras County and Beyond Weather
Amador Angels Camp Arnold Bear Valley Copperopolis Murphys San Andreas Valley Springs Moke Hill/West Point Tuolumne
Business Directory
Weather & Roads
Real Estate
Weekly & Grocery Ads
Life & Style
Law Enforcement
Wine News
Health & Fitness
Home & Garden
Food & Dining
Religion & Faith
Frogtown USA
Legal Notices
Free Classifieds
Letters to the Editor
About Us

Coming Soon...
Tuesday, Jun 2
10:00 AM Hospice of Amador & Calaveras Offering Weekly Grief Support
05:00 PM Angels Camp City Council Back in Action on June 2nd
06:00 PM Taco Tuesdays Are Back with Socially Distanced Live Entertainment Starting June 2nd!!
Wednesday, Jun 3
06:00 PM Overeaters Anonymous (OA)
Friday, Jun 5
All Day Get Your Fill of Fish & Chips Every Friday at Gooney's Bar & Grill
Saturday, Jun 6
All Day Bistro Espresso is Open late until 8:00pm! Join Us & Bring a Friend!
Sunday, Jun 7
All Day Our Sunday Edition with Local Features, Local Specials & More Every Sunday All Day Long!
Tuesday, Jun 9
10:00 AM Hospice of Amador & Calaveras Offering Weekly Grief Support
Wednesday, Jun 10
06:00 PM Overeaters Anonymous (OA)
Thursday, Jun 11
08:00 PM Thursdays is Karaoke Night at Gooney's Bar & Grill
Friday, Jun 12
All Day Get Your Fill of Fish & Chips Every Friday at Gooney's Bar & Grill
Sunday, Jun 14
All Day Our Sunday Edition with Local Features, Local Specials & More Every Sunday All Day Long!

Search Announcements

Log In


Remember Me

Posted by: thepinetree on 05/18/2020 12:46 PM Updated by: thepinetree on 05/18/2020 12:46 PM
Expires: 01/01/2025 12:00 AM

Moderna Announces Positive Interim Phase 1 Data for its Vaccine Against Novel Coronavirus

Cambridge, MA...Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg dose levels. All participants ages 18-55 (n=15 per cohort) across all three dose levels seroconverted by day 15 after a single dose. At day 43, two weeks following the second dose, at the 25 µg dose level (n=15), levels of binding antibodies were at the levels seen in convalescent sera (blood samples from people who have recovered from COVID-19) tested in the same assay. At day 43, at the 100 µg dose level (n=10), levels of binding antibodies significantly exceeded the levels seen in convalescent sera. Samples are not yet available for remaining participants.

At this time, neutralizing antibody data are available only for the first four participants in each of the 25 µg and 100 µg dose level cohorts. Consistent with the binding antibody data, mRNA-1273 vaccination elicited neutralizing antibodies in all eight of these participants, as measured by plaque reduction neutralization (PRNT) assays against live SARS-CoV-2. The levels of neutralizing antibodies at day 43 were at or above levels generally seen in convalescent sera.

mRNA-1273 was generally safe and well tolerated, with a safety profile consistent with that seen in prior Moderna infectious disease vaccine clinical studies. The sole incidence of a grade 3 adverse event in the 25 µg and 100 µg dose cohorts was a single participant at 100 µg who experienced grade 3 erythema (redness) around the injection site. To date, the most notable adverse events were seen at the 250 µg dose level, comprising three participants with grade 3 systemic symptoms, only following the second dose. All adverse events have been transient and self-resolving. No grade 4 adverse events or serious adverse events have been reported.

Preclinical results from a viral challenge study in mice conducted in collaboration with NIAID and its academic partners are also available. In this study, vaccination with mRNA-1273 prevented viral replication in the lungs of animals challenged with SARS-CoV-2. Neutralizing titers in Phase 1 clinical trial participants at the 25 µg and 100 µg dose levels were consistent with neutralizing titers that were protective in the mouse challenge model.

Based on the interim Phase 1 data, the Moderna-led Phase 2 study will be amended to study two dose levels, 50 µg and 100 µg, with the aim of selecting a dose for pivotal studies. The NIAID-led Phase 1 study is being amended to include a 50 µg dose level cohort across each of the three age groups. Moderna anticipates the dose for the Phase 3 study to be between 25 µg and 100 µg and expects Phase 3 trial initiation in July, subject to finalization of the clinical trial protocol.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”

“With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” said Stéphane Bancel, Chief Executive Officer at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”

Funding from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), supported the planning for the Phase 2 and Phase 3 studies of mRNA-1273 and will also support the execution of these studies, as well as the scale-up of mRNA-1273 manufacturing both at the Company’s facilities and that of its strategic collaborator, Lonza Ltd.

Conference Call and Webcast Information

Moderna will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 18, 2020. To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 2186342. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at The archived webcast will be available on Moderna’s website approximately two hours after the conference call.

About mRNA-1273

mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing.

On May 6, the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application for mRNA-1273 allowing it to proceed to a Phase 2 study, which is expected to begin shortly. On May 12, the FDA granted mRNA-1273 Fast Track designation. Moderna is finalizing the protocol for a Phase 3 study, expected to begin in July 2020. A summary of the company’s work to date on SARS-CoV-2 can be found here.

About Moderna’s Prophylactic Vaccines Modality

Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,400 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.

The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated manufacturing plant which enables the promise of the technology platform.

Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

Vaccines against respiratory infections

Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)
RSV vaccine for young children (mRNA-1345)
Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653)
Novel coronavirus (SARS-CoV-2) vaccine (mRNA-1273)
Influenza H7N9 (mRNA-1851)
Vaccines against infections transmitted from mother to baby

Cytomegalovirus (CMV) vaccine (mRNA-1647)
Zika vaccine (mRNA-1893 with BARDA)
Vaccines against highly prevalent viral infections

Epstein-Barr virus (EBV) vaccine (mRNA-1189)
To date, Moderna has demonstrated positive Phase 1 data readouts for seven prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3, CMV and Zika). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past five years. To learn more, visit

Comments - Make a comment
The comments are owned by the poster. We are not responsible for its content. We value free speech but remember this is a public forum and we hope that people would use common sense and decency. If you see an offensive comment please email us at
No Subject
Posted on: 2020-05-18 12:58:50   By: Anonymous
President Trump predicted that there would be a vaccine by the end of the year and here it is. Let's see how many negative comments that we get from the A-Hole Democrats that don't want a vaccine so they can say that the President doesn't know what he is talking about.

[Reply ]

    Posted on: 2020-05-18 13:32:40   By: Anonymous
    People who talk sh t will be reincarnated as toilet paper

    [Reply ]

    Re: know what he's talking about
    Posted on: 2020-05-18 13:52:42   By: Anonymous
    A vaccine would be wonderful.
    If you read carefully, these results are from a phase 1 study. On very few individuals. Also some results on tests on mice.
    I'm an optimistic person. With so many labs working on this, one of them should come up with something soon.
    Like with hydrocloroquine, you can't just start giving this stuff to everyone.
    January 2021 will come quickly.
    November 2020 can't come soon enough.
    The virus doesn't care what political party you belong to.
    The voters need to make the right choice to who can lead the US through good and bad times.

    [Reply ]

      Re: know what he's talking about
      Posted on: 2020-05-18 14:01:59   By: Anonymous
      It's always the Democrats who put negative comments on any positive news about the Coronavirus as it seems that they want the Trump Administration to fail. It's the Democrats that are going to fail in November.

      [Reply ]

        Re: know what he's talking about
        Posted on: 2020-05-18 15:35:55   By: Anonymous
        Along with scientists and medical professionals.

        [Reply ]

        Re: know what he's talking about
        Posted on: 2020-05-18 15:39:47   By: Anonymous
        As if the GOP had anything positive to say and blocked many efforts including affordable health care when President Obama was in office. Imagine more than a few of you might be wishing for that in the coming months. Your memory is short and the GOP is counting on it.

        [Reply ]

    Posted on: 2020-05-18 20:39:37   By: Anonymous
    ^Hey numbskull, they can come up with hundreds of vaccines by the end of the year. Will studies be performed with results showing their safety and efficency by then? No, release of a vaccine is in a miracle scenario, available in two years.Keep eating the Trump bs though.

    [Reply ]

    Posted on: 2020-05-18 21:06:10   By: Anonymous
    Not trying to be disrespectful to you, and I'm not a Democrat. With that being said, they gave up trying to make a vaccine for the original SARS long ago. If they come up with a vaccine for this SARS they would have solved AIDS. I just don't see any of it happening.

    [Reply ]

No Subject
Posted on: 2020-05-18 21:54:18   By: Anonymous
The Democrats wanted to get the COVID death numbers up so they initially encouraged large social gatherings and mandated that sick, positive patients be transferred to nursing homes. They want the economy to tank, so they pushed to close businesses, to make people stay home from work, and to waste trillions on their pork projects in the stimulus bills instead of having all of the money go to taxpayers affected by the coronavirus. Now, dissatisfied with just disinfectant and toilet paper shortages, they want to have food shortages as well. Way to go for caring so much!

[Reply ]

    Re: promoted large gatherings?
    Posted on: 2020-05-19 06:56:12   By: Anonymous
    Oh, you must be inferring Pelosi's jaunt into Chinatown.
    Trump was still holding rallies into March and you think it's the Democrats that encouraged large gatherings.
    Trump has encouraged mass protests in states that would NOT reopen since midApril.
    You really need to pick different news sites.
    Find one from Asia or even BBC. They will at least try to present facts.
    We need a president that leads by example. Not one that does the opposite of what the experts say.
    Unstable idiot.
    Puts on a dog and pony show each day so that his supporters think he's doing something.
    What a freakin joke.
    He's got a crazy look in his eyes.
    Kinda glazed over too.
    Must be the hydrocloroquine kicking in.
    Or is it malaria?

    [Reply ]

      Re: promoted large gatherings?
      Posted on: 2020-05-19 07:28:05   By: Anonymous
      Look closely people. Look closely into his eyes, the look. That is the look of evil. And it has come to the White House.

      [Reply ]

        Re: promoted large gatherings?
        Posted on: 2020-05-19 07:28:48   By: Anonymous
        Manchurian Candidate?

        [Reply ]

          Re: promoted large gatherings?
          Posted on: 2020-05-19 07:40:22   By: Anonymous
          ^^^ STFU tooth pick dick

          [Reply ]

          Re: promoted large gatherings?
          Posted on: 2020-05-19 07:47:59   By: Anonymous
          Nope. Moscow candidate. Complete with golden showers.
          Melania has stuck by him though.
          Or is she just stuck?

          [Reply ]

        Re: promoted large gatherings?
        Posted on: 2020-05-19 20:10:52   By: Anonymous
        Then look at Pelosi! You decide

        [Reply ]

No Subject
Posted on: 2020-05-19 10:12:29   By: Anonymous
If Democrats want Covid-19 numbers up why are they the ones supporting stay at home, social distancing, and cautiously reopening the economy? Conservatives are a funny bunch, silly little guys.

[Reply ]

No Subject
Posted on: 2020-05-20 08:41:09   By: Anonymous
And now this study has been debunked by scientists who are saying they did not have accurate data numbers or enough test cases.
Just Google the term Moderna and read the facts.

[Reply ]

What's Related
These might interest you as well
Local News


Photo Albums

phpws Business Directory

RSS News Feeds

Web Pages

Mark Twain Medical Center
Meadowmont Pharmacy
Bank of Stockton
Bear Valley Real Estate
Bear Valley Cross Country
Cedar Creek Realty
Cave, Mine & Zip Lines
Fox Security
Bistro Espresso
Pinnacle Physical Therapy
Chatom Winery
Middleton's Furniture
Bear Valley Mountain Resort
Paul D. Bertini
Premier Properties
High Country Spa & Stove
Calaveras Mentoriing

Ebbetts Pass Scenic Byway
Sierra Logging Museum
Jenny's Kitchen

Copyright © The Pine Tree 2005-2020